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Accelerating cryoprotectant 
diffusion kinetics improves 
cryopreservation of pancreatic 
islets
Nikola Dolezalova1,2, Anja Gruszczyk3, Kerry Barkan4,5, John A. Gamble1, Sam Galvin6, 
Till Moreth7, Kevin O’Holleran8, Krishnaa T. Mahbubani1, Jackie A. Higgins1, 
Fiona M. Gribble6, Frank Reimann6, Jakub Surmacki9, Simon Andrews10, John J. Casey11, 
Francesco Pampaloni7, Michael P. Murphy3,12, Graham Ladds4, Nigel K. H. Slater2 & 
Kourosh Saeb‑Parsy1*
Cryopreservation offers the potential to increase the availability of pancreatic islets for treatment 
of diabetic patients. However, current protocols, which use dimethyl sulfoxide (DMSO), lead to poor 
cryosurvival of islets. We demonstrate that equilibration of mouse islets with small molecules in 
aqueous solutions can be accelerated from > 24 to 6 h by increasing incubation temperature to 37 °C. 
We utilize this finding to demonstrate that current viability staining protocols are inaccurate and to 
develop a novel cryopreservation method combining DMSO with trehalose pre‑incubation to achieve 
improved cryosurvival. This protocol resulted in improved ATP/ADP ratios and peptide secretion 
from β‑cells, preserved cAMP response, and a gene expression profile consistent with improved 
cryoprotection. Our findings have potential to increase the availability of islets for transplantation 
and to inform the design of cryopreservation protocols for other multicellular aggregates, including 
organoids and bioengineered tissues.
Despite almost a century of experience with exogenous insulin therapy, diabetes remains a major cause of heart 
disease, blindness, kidney failure and lower extremity  amputation1–4. Less than 20% of patients with type 1 dia-
betes mellitus (T1DM) currently achieve recommended treatment targets necessary to reduce risks of diabetic 
 complications5. Whole pancreas  transplantation6 or pancreatic islet  transplantation7 offer potential curative 
treatments but are offered to a very small proportion of (< 0.5%) patients with  T1DM8,9. Whole pancreas trans-
plantation is a highly invasive surgical procedure with high risk of  complications10. Transplantation of isolated 
pancreatic  islets11 is a less invasive procedure that involves the infusion of only the endocrine islets into the portal 
vein. Availability of islets is a key limiting factor for access to islet transplantation and, due to an insufficient 
yield of islets from a single donor, approximately half of  patients11 require islet infusions from two or more islet 
donors to achieve insulin independence. Fresh islets can only be cultured for a few  days12 and lack of a clinically 
relevant cryopreservation protocol prevents islets isolated from different donors to be preserved and combined. In 
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addition to extending the pool of available islets, effective cryopreservation would enable more time for accurate 
screening and matching of islets to recipients, and remove some of the logistical challenges of  transplantation13.
Cryopreservation of cell clusters such as pancreatic islets presents significant additional and unresolved 
challenges compared to single cells. Pancreatic islets vary largely in size (with average diameter of 109 μm in 
human)14,15 and are composed of densely packed cells. In the absence of perfusion through the vasculature 
ex vivo, diffusion of solutes into the core of islets necessitates long incubation times. This is problematic if the 
solute is toxic to cells, as is the case with the commonly used cryoprotectant dimethyl sulfoxide (DMSO)16. 
Furthermore, different cell layers within the islets are subjected to unequal cryoprotectant and intracellular 
water concentrations, as well as to non-uniform temperature changes during cryopreservation, which can lead 
to increased and differential ice crystal  formation17.
One strategy to achieve homogeneous exposure of islet cells to DMSO during cryopreservation is the sequen-
tial incubation of islets with different DMSO concentrations for different durations (e.g., in 0.67 M DMSO for 
5 min at 22 °C, followed by incubation in 1 M DMSO for 25 min at 22 °C and final incubation in 2 M DMSO for 
15 min at 0 °C before freezing)18. Studies on diffusion of DMSO into islets suggest that these incubation times 
may be sufficient for equilibration into the core of  islets19,20. However, there is limited data on diffusion rates of 
other cryoprotectants, including non-penetrating cryoprotectants such as sugars. Another strategy to improve 
cryopreservation is the use of a combination of cryoprotectants to reduce exposure to toxic  concentrations21. 
Trehalose and other non-penetrating cryoprotectants have been used as additives for cryopreservation of a variety 
of single  cells22–24 and  islets25,26, although it is not clear whether these protocols resulted in enhanced cryopro-
tection compared to DMSO alone. Despite their potential, these strategies have not led to the development of a 
clinically used islet cryopreservation protocol, which remains an unmet need. Importantly, a clinically-relevant 
protocol for islet cryopreservation would have potential applications for preservation of other multicellular 
aggregates such as organoids and bioengineered  tissues27.
In this study, we developed a method to determine diffusion kinetics of small molecules in aqueous solutions 
into the core of pancreatic islets and to investigate strategies to accelerate it. Based on these results, we designed 
a cryopreservation protocol which combines DMSO with trehalose pre-incubation to achieve improved post-
thaw viability.
Results
Standard incubation times are not sufficient to achieve solute equilibration. We first quantified 
diffusion kinetics of solutes in aqueous solutions into the core of mouse pancreatic islets. Clinical assessment 
of islet viability typically involves dual fluorescent staining with fluorescein diacetate (FDA) and propidium 
iodide (PI) for 15 min or less at room temperature (Supplementary Fig. 1). Using this protocol, we observed 
good staining of peripheral cells on laser scanning confocal microscopy, but little or no signal from cells located 
deeper than 20–30 μm from the periphery of islets (Fig. 1a). As both diffusion kinetics and imaging limitations 
could have contributed to lack of staining of the islet core, we developed a method to investigate the need for 
longer incubation of islets with small molecules. We incubated islets with Hoechst 33342 dye, which is resistant 
to photo-bleaching and stains all cells irrespective of their viability, for different durations, followed by arrest of 
diffusion by freezing (Fig. 1b). Frozen sections of the dye-loaded islets thus enabled measurement of the depth 
of diffusion of the dye from the surface of the islets (Fig. 1c). The intensity of staining towards the central core of 
islets increased with prolonged incubation, but the core of the islets remained minimally stained even after 12 h 
of incubation at room temperature (Fig. 1d). The intensity of staining was in line with Fick’s law (Fig. 1e), which 
states that the square of the distance of the penetration by diffusion increases linearly with the time allowed for 
 penetration28. This correlation is consistent with the hypothesis that molecular diffusion is primarily responsible 
for the movement of dye molecules in this system.
Increasing temperature can accelerate solute diffusion. Incubation times > 12 h present a practical 
obstacle to assessment of viability and cryopreservation of islets in clinical setting. We therefore investigated 
strategies to accelerate diffusion into the core of pancreatic islets. Increasing hydrostatic pressure through cen-
trifugation resulted in an elevated concentration of dye molecules on the surface of the islets but only a marginal 
increase in the depth of diffusion (Supplementary Fig. 2a,b). DMSO is known to have high  diffusivity19 and its 
properties as an enhancer of penetration across membranes is well  described29. Although 10% (but not 1%) 
DMSO enhanced the diffusion rate significantly (Supplementary Fig. 2c–f), it led to significant necrosis-related 
karyolysis at the periphery of the islets (Supplementary Fig. 2g,h). We finally investigated the effect of tempera-
ture on diffusion of Hoechst 33342 in islets. At room temperature, staining of the islet core was much lower than 
the periphery even after 24 h of incubation (Fig. 2a). At 37 °C, however, islets were homogeneously stained after 
only 6 h of incubation (Fig. 2b, Supplementary Fig. 2i). Importantly, viability of the islets incubated with the dye 
for 6 h at 37 °C remained above 90% (Supplementary Fig. 2j). We next imaged pancreatic islets after incubation 
with viability dyes for 6 h at 37 °C. The optical properties of the islets prohibited adequate imaging of the core of 
the islets using scanning confocal microscopy (Fig. 2c) or two-photon excitation microscopy (Fig. 2d). However, 
light-sheet microscopy (Fig. 2e,f) clearly demonstrated the presence of dead cells at the core of islets while the 
periphery consisted of viable cells.
Pre‑incubation with trehalose improves post‑thaw islet survival. To develop a new cryopreser-
vation method for islets, we first optimised published  freezing30 and  thawing31 protocols using DMSO alone 
(Supplementary Fig.  3a–c). As expected, freezing with the non-toxic cryoprotectant trehalose alone did not 
provide sufficient cryoprotection, regardless of incubation time and trehalose concentration (Supplementary 
Fig. 3d,e). We therefore next explored combining pre-incubation with trehalose followed by addition of DMSO 
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as a cryopreservation method. After evaluating the toxicity of trehalose at a range of concentrations (Supple-
mentary Fig. 3f), we used the highest non-toxic concentration of trehalose (200 mM). To develop the proto-
col, we pre-incubated islets with trehalose for 1, 3, 6, 24 or 48 h at 37 °C, added DMSO in the last 45 min and 
cryopreserved islets using a controlled-rate freezer (Fig. 3). Pre-incubation with trehalose for 6 h (DT6h group) 
resulted in significant improvement of viability 24 h after thawing compared to DMSO alone (Fig. 4a). Individual 
islet viabilities displayed the expected distribution immediately after thawing (Fig. 4b) but shifted towards a 
bimodal distribution at 24 h, with islets separating into two groups: viability of some islets was close to 100% and 
the remainder close to the minimum of 0% (Fig. 4c). There was a significant positive correlation between the 
islet size and viability at 24 h post-thaw in the DT6h group and at both time points in the DMSO group (Sup-
plementary Fig. 4a,b). The DT6h group yielded the most islets in the 67–100% viability group at both times of 
measurement (Fig. 4d,e). There was no difference in post-thaw islet yield (number of islets recovered) and islet 
size in the DT6h group compared to cryopreservation with DMSO only (Fig. 4f,g, Supplementary Fig. 4c for raw 
data). Post-thaw islet morphology was maintained in both groups, with DT6h showing less debris detected on 
the surface of islets or in the free medium at 24 h after thawing (Supplementary Fig. 4d).
Figure 1.  Molecular diffusion into islets—imaging and method development. (a) Lateral optical cross-sections 
of a pancreatic islet on top of a coverslip (unflattened) imaged by a confocal microscope (FDA/PI/Hoechst 
33342 staining for 15 min at room temperature); each slice is labelled with distance in μm from the top of the 
islet. (b) Novel method to study diffusion: isolated pancreatic islets were incubated with Hoechst 33342 nuclear 
stain under different conditions, washed and immediately embedded into Optimal Cutting Temperature 
compound (O.C.T.) to stop the diffusion of the dye further into the islet. Frozen sections were cut on a cryostat 
and coverslip was added using a dry mounting method (double-sided tape) to prevent any exposure to moisture. 
Each slide was imaged immediately after being thawed to prevent further diffusion of the dye into the islet. (c) 
Confocal images of the sectioned islets were analysed using ImageJ plugin Concentric Circles. Parameters of 
the plugin were set to align with the outer edge of the imaged islet and to draw circles 5 pixels (corresponding 
to 1.89 μm) apart. Average intensity of each circle was measured, and results were plotted to show a staining 
profile. (d) Average staining profiles of pancreatic islets incubated with Hoechst 33342 at room temperature for 
15 min, 6 h or 12 h (n = 3–5 islets). To get an average staining profile for a certain staining condition, profiles 
from multiple islets were aligned at the outer edge (0 μm). (e) Linear relationship between time and square of 
distance shown for four different fluorescent intensities from plot shown in (c). Figure (b) was created using 
Inkscape (version 0.91, http:// www. inksc ape. org/), figures (d) and (e) using GraphPad Prism (version 8.4.1, 
https:// www. graph pad. com). RFU relative fluorescence intensity.
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The novel protocol maintains ATP/ADP ratios and cyclic AMP response. Mitochondrial markers 
are recognise as important parameters in evaluation of pancreatic islet health and are currently one of the most 
reliable predictors of in vivo islet  function32,33. Relative to control fresh islets, cryopreservation using the DT6h 
protocol maintained ATP/ADP ratio better than DMSO (77.3 ± 24.7% vs. 54.0 ± 22.7%; p = 0.0057, Fig. 5a). In 
both cryopreserved conditions, there was a significant decrease in the absolute concentration of adenosine 
nucleotides, likely caused by the loss of viable cells during cryopreservation (Supplementary Fig. 4e). Consist-
ent with a key role for reactive oxygen species and mitochondrial injury during cryopreservation, the addition 
of the mitochondria-targeted antioxidant  MitoQ34 to the DT6h protocol further improved ATP/ADP ratio to a 
level comparable to fresh islets (Fig. 5a). Both DMSO- and DT6h-cryopreserved islets showed increased DNA 
damage (manifested as reduced  amplification35,36), which could be partially rescued by the addition of MitoQ 
Figure 2.  Effect of temperature on diffusion of nuclear dye Hoechst 33342 into pancreatic islets. (a) Staining 
profiles of pancreatic islets incubated with Hoechst 33342 for 15 min, 6 h or 24 h at room temperature (n = 6–7). 
(b) Staining profiles of pancreatic islets incubated with Hoechst 33342 for 15 min, 6 h or 24 h at 37 °C (n = 6–7). 
(c) Pancreatic islet stained with FDA (green), PI (magenta) and Hoechst 33342 (white) for 6 h at 37 °C imaged 
a confocal microscope. (d) Pancreatic islet stained with FDA (green) and Hoechst 33342 (white) for 6 h at 37 °C 
imaged on a two-photon microscope. (e) Pancreatic islet stained with FDA (green), PI (magenta) and Hoechst 
33342 (white) for 6 h at 37 °C imaged on a light sheet microscope. (f) 3D-reconstruction from multi-angle 
imaging (4 angles, 90° apart) of pancreatic islet stained with FDA (green), PI (magenta) and Hoechst 33342 
(white) using light sheet microscopy. Representative images shown. Figures (a) and (b) were produced in 
GraphPad Prism (version 8.4.1, https:// www. graph pad. com). In (c–a), each slice is labelled with distance in μm 
from the top of the islet. FDA fluorescein diacetate, PI propidium iodide.
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(Fig. 5b). The ATP/ADP ratios and mitochondrial DNA oxidation levels were reflected in the post-thaw viability 
scores in the three groups (Supplementary Fig. 4f). To examine the integrity of intracellular pathways regulating 
insulin secretion, we next investigated activation of adenylyl cyclase and production of cyclic AMP (cAMP)37 in 
fresh and cryopreserved islets. cAMP production induced by the adenylate cyclase activator forskolin (Fig. 5c) 
and incretin hormone GLP-1 (Fig. 5d) was comparable in fresh, DMSO- and DT6h-cryopreserved islets, sug-
gesting that this pathway remains intact after cryopreservation using both methods.
The novel protocol maintains peptide secretion from β‑cells. Using mass spectrometry-based pep-
tidomics, we next screened peptide secretion by pancreatic islets exposed to two glucose concentrations. Both 
DMSO- and DT6h-cryopreserved islets remained responsive to increased glucose concentration by increasing 
the release of insulin (Fig.  6a,b) and IAPP (islet amyloid polypeptide) which is co-stored and released with 
insulin (Fig. 6c). DMSO-cryopreserved islets showed a significantly lower fold-change in insulin release for both 
insulin-1 and insulin-2 (duplicate genes in mouse genome, Fig. 6d,e) and dysregulated release of IAPP (Fig. 6f). 
DT6h showed an insulin and IAPP release profile more similar to fresh islets, with low insulin release in 3.3 mM 
glucose and its upregulation in 16.7 mM glucose (Fig. 6a,b). Glucagon and somatostatin were detected in very 
low quantities in media from all three groups. Both DMSO- and DT6h-cryopreserved islets showed highly vari-
able secretion profiles (Fig. 6g,h) and fold changes for both peptides (Fig. 6i,j).
Transcriptomic differences in insulin production and stress response pathways. We compared 
RNA isolated from fresh, DMSO- or DT6h-cryopreserved islets as outlined in Fig. 7a.  DESeq238 comparison 
to fresh islets revealed 2423 and 2870 differentially expressed genes in the DMSO and DT6h groups, respec-
tively. Heatmap visualisation of a three-group comparison using DESeq2 shows the differences between fresh 
and frozen samples but also a level of variability between the frozen sample replicates (Supplementary Fig. 5). 
A second analysis of differential gene expression, using the Intensity Difference filter native to  SeqMonk39,40, 
was then carried out to identify genes with the highest fold-change relative to their expression level. There was 
an overlap of 142 differentially expressed genes between these two analyses, clustering into three main gene 
clusters (Fig. 7b,c). Of these, Clusters 1 and 3 show genes which were up- or down-regulated in both cryopre-
served groups when compared to fresh, and Cluster 2 consists of 16 genes which were down-regulated in DMSO 
but showed similar level in fresh and DT6h groups. These included genes that are involved in the uptake and 
metabolism of cholesterol (Insig1, Fdps, Pcsk9, Lss, Cln6, Msmo1 and Vegfb), stress responders and regulators of 
apoptosis (Vegfb, Pcsk9, Flcn and Fnip2).
Preranked Gene Set Enrichment Analysis (GSEA-Preranked) showed large differences between fresh and 
cryopreserved islets, with ten gene sets downregulated and 27 upregulated in DMSO and nine downregulated 
and 24 upregulated in DT6h (Suppl. Fig. 6a,b). Both cryopreserved groups showed downregulation of the ‘protein 
Figure 3.  Schematic of the proposed islet cryopreservation protocol. (a) Changes in concentrations of 
cryoprotectants in the cryopreservation solution over time. (b) Changes in temperatures of the cryopreserved 
sample over time of the cryopreservation (time of freezing is t = 0 min). Islets are preincubated in 200 mM 
trehalose at 37 °C for 6 h (trehalose is kept at stable concentration throughout the incubation). 45 min before 
the end of this incubation time, step-wise DMSO addition protocol is initiated and samples are frozen in a 
programmable freezer. Frozen samples are plunged into liquid nitrogen and stored in a liquid nitrogen dewar 
until thawing. Thawing is performed in a 37 °C water bath until sample reaches 0 °C and CPAs are removed 
using a step-wise protocol. Thawed islets are transferred into a fresh culture medium and can be cultured at 
37 °C. CPA cryoprotectant, LN liquid nitrogen.
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secretion’ and ‘pancreatic beta cell’ signatures which is in line with Ins1 and Ins2 being identified as the most 
down-regulated genes in both cryopreserved conditions when compared to fresh (− 6.80 and − 6.83 fold change 
for DMSO, − 6.59 and − 5.96 fold change for DT6h). GSEA comparison of DMSO and DT6h showed fewer 
differences, with 14 gene sets showing lower and three gene sets higher relative expression in DT6h (Fig. 7d). 
Relative to the DMSO group, the DT6h group showed decreased expression of proliferation, pro-inflammatory, 
hypoxia- or apoptosis-related gene sets, among others. Conversely, the ‘cholesterol homeostasis’ gene set showed 
higher expression in the DT6h dataset than in DMSO. The above gene sets followed the same direction of change 
for both DMSO and DT6h when compared to the fresh group. Similar results were produced by pathway analysis 
against the more granular Gene Ontology: Biological Process gene set. There was an upregulation in vesicular 
transport, lipid metabolism and response to insulin in the DT6h group, and a reduction in oxidative stress, 
immune activation and cell differentiation (Supplementary Fig. 7). Of note, there were no differences in insulin 
exocytosis pathways (Supplementary Table 2).
In vivo performance of cryopreserved islets remains variable. To evaluate the performance of the 
two cryopreservation techniques in  vivo, we transplanted 800 fresh, DMSO- and DT6h-cryopreserved islets 
under the kidney capsule of streptozotocin-induced diabetic mice. The dose of 800 islets was chosen over lower 
doses (300 or 400 islets) because it reliably restored normoglycaemia in all mice transplanted with fresh islets 
(Supplementary Fig.  8). There was no difference in the blood glucose levels between the DMSO and DT6h 
groups. Both groups showed higher glucose levels over time than mice transplanted with fresh islets but lower 
levels than animals transplanted with the vehicle (Matrigel) only (Fig. 8a). At the end of the experiment, the 
average blood glucose levels were 5.1 ± 1.5 for fresh islets, 30.5 ± 21.2 for DMSO-cryopreserved islets, 32.0 ± 20.0 
for DT6h-cryopreserved islets and 48.0 ± 11.8 for Matrigel (Fig. 8b). In the group transplanted with fresh islets, 
all mice achieved normoglycaemia by 6 days post-transplantation. The two cryopreserved groups showed high 
variability between animals (Fig. 8c–f).
Human pancreatic islet cryopreservation protocol needs further optimisation. We performed a 
pilot study to evaluate whether the cryopreservation protocol developed for mouse islets could be directly trans-
lated to human. Islets from three human donors (Supplementary Table 1) showed a post-thaw viability of ~ 60% 
Figure 4.  Viability, size and number recovered using the proposed islet cryopreservation protocol. (a) Post-
thaw viability of pancreatic islets cryopreserved with proposed DMSO + trehalose protocol with varying 
trehalose pre-incubation time (1–48 h). Viability measured immediately post-thaw (light blue bars) and 24 h 
post-thaw (dark blue bars) shown. Bars represent mean ± SD, n = 3 islet isolations, repeated measures two-way 
repeated measures ANOVA followed by Tukey’s HSD post-hoc test, all groups were significantly different from 
trehalose only (Treh), other significant differences (p ≤ 0.05) are marked by asterisks. (b) Post-thaw viability 
of individual islets from the experiments shown in (a) measured immediately post-thaw and (c) 24 h post-
thaw. Triangles represent individual islet viabilities; triangles of same colour represent results from the same 
experiment. (d) Distribution of islets from (a) in three viability groups for DMSO- and DT6h-cryopreserved 
islets immediately post-thaw and (e) 24 h post-thaw. (f) Post-thaw islet yield for islets cryopreserved with 
DMSO or DT6h, calculated as number of islets recovered after thawing/number of islets before freezing. (g) 
Average islet diameter of DMSO- and DT6h-cryopreserved islets measured pre-freeze, 0 h post-thaw and 24 h 
post-thaw. All figures were produced using GraphPad Prism (version 8.4.1, https:// www. graph pad. com). DT6h 
DMSO + trehalose pre-incubated for 6 h, Treh trehalose only.
7
Vol.:(0123456789)
Scientific Reports |        (2021) 11:10418  | https://doi.org/10.1038/s41598-021-89853-6
www.nature.com/scientificreports/
immediately and ~ 40% at 24 h post-thaw in all cryopreserved conditions except with no cryoprotectant which 
was close to 0%. However, a clear benefit of trehalose addition and the trend between the different trehalose 
pre-incubation times (1, 3 or 6 h) shown for mouse islets (Fig. 4a) was not be observed for human islets in these 
preliminary experiments (Supplementary Fig. 9).
Figure 5.  Metabolic data for islets cryopreserved using the proposed protocol (DT6h). (a) ATP/ADP ratio 
of cryopreserved islets 24 h post-thaw normalised to ATP/ADP ratio in fresh islets (n = 9 islet isolations). (b) 
Mitochondrial DNA oxidation levels in fresh, DMSO-cryopreserved and DT6h-cryopreserved islets. Higher 
amplification numbers indicate lower oxidation of mitochondrial DNA (n = 4 islet isolations). (c) Cyclic AMP 
(cAMP) production in fresh, DMSO-cryopreserved and DT6h-cryopreserved islets upon exposure to forskolin 
or (d) GLP-1. Data in (c) and (d) shown as raw values of the fluorescence resonance energy transfer (FRET) 
signal at 665 nm, which is inversely proportional to the cAMP concentration in the samples. Data obtained from 
the same islet sample are connected with a line (n = 8–9 islet isolations). Missing data were below the detection 
level of the assay. Repeated measures one-way ANOVA followed with Tukey’s HSD post-hoc test was performed, 
statistically significant differences are marked by asterisks: *p ≤ 0.05, **p ≤ 0.01. All figures were produced using 
GraphPad Prism (version 8.4.1, https:// www. graph pad. com).
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Figure 6.  Peptide production by islets after glucose stimulation. Peptide levels measured by LC–MS/MS for 
(a) mouse insulin-1, (b) mouse insulin-2 and (c) islet amyloid polypeptide (IAPP). Fold changes calculated 
as the ratio of Peak Area measured in 16.7 mM glucose and in 3.3 mM glucose for (d) mouse insulin-1, (e) 
mouse insulin-2, (f) islet amyloid polypeptide (IAPP). Peptide levels measured by LC–MS/MS for (g) glucagon 
and (h) somatostatin (SST-14). Fold changes calculated as the ratio of Peak Area concentration measured in 
16.7 mM glucose and in 3.3 mM glucose for (i) glucagon and (j) somatostatin (SST-14). Peak Areas for glucagon 
were normalised to Peak Areas for glucagon internal standard. One-way Kruskal–Wallis analysis of variance 
was performed for the fold changes followed by Dunn’s correction for multiple comparisons (n = 9 samples 
from 3 isolations, each sample = 10 islets; p-values are shown for each comparison, significant differences are 
highlighted in red). All figures were produced in GraphPad Prism (version 8.4.1, https:// www. graph pad. com).
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Figure 7.  Impact of cryopreservation on islet transcriptome. (a) Schematic representation of the experimental 
design. Islets from three separate isolations (n = 3) were used as shown and samples were stored in RNAlater 
solution. RNA from all samples was processed and sequenced on the same occasion. (b) Heatmap showing 
the 142 genes that are differentially expressed between the three tested conditions (genes common to both 
the DESeq2 and Intensity Difference analysis, FDR ≤ 0.05, n = 3 islet isolations, individual replicates shown), 
clustered based on the hierarchical cluster analysis. (c) Line graph representation of the gene clusters 1, 2 and 3, 
re-plotted from (b). (d) Preranked Gene Set Enrichment Analysis (GSEA-Preranked) of relative differences in 
Hallmark gene set expression levels between DMSO- and DT6h-cryopreserved islets (differences of FDR ≤ 0.05 
are shown). The gene sets are grouped according to the Process Categories of the Molecular Signatures Database 
Hallmark Gene Sets (see “Methods”). FDR q-values are highlighted in different shades of red. Figure (a) was 
created using Inkscape (version 0.91, http:// www. inksc ape. org/), figures (b) and (c) using  SeqMonk39 (version 
1.45.4) and figure (d) using GraphPad Prism (version 8.4.1, https:// www. graph pad. com).
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Discussion
In this study, we describe a method for measuring diffusion rates for small molecules in aqueous solutions into 
the core of non-vascularised tissue using Hoechst 33342 dye. While this serves as a useful approximation, other 
small molecules, including trehalose and viability dyes, may follow different diffusion rates based on their con-
centration gradient or ability to cross the membrane. Other properties modulating the diffusion rate of molecules 
include molecular weight, charge or hydrophobicity and therefore, empirical evidence should be obtained for 
each cryoprotectant of interest to adjust any estimates or approximations. Diffusion of Hoechst 33342 into the 
islet core was accelerated from > 24 to 6 h by increasing temperature to 37 °C, without detrimental effect on 
viability. In addition to utility in islet cryopreservation, this approach can be used for clinically relevant islet 
transplant pre-conditioning protocols, such as incubation with antioxidants to ameliorate oxidative damage. 
Figure 8.  Engraftment of cryopreserved islets in STZ-induced diabetes mouse model. (a) Fasting blood glucose 
measurements in diabetic mice transplanted with 800 fresh, DMSO-cryopreserved or DT6h-cryopreserved islets 
or vehicle (Matrigel), measured using portable glucose meter (n = 3–4 mice). (b) Fasting blood serum glucose 
measured using an immunoassay on day 75 days after transplantation (day 91 after first STZ injection). (c–f) 
Fasting blood glucose in individual diabetic mice transplanted with (c) 800 fresh islets, (d) Matrigel/vehicle 
only, (e) 800 DMSO-cryopreserved islets and (f) 800 DT6h-cryopreserved islets over the time course of the 
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RNA sequencing revealed upregulation of hypoxia-related genes in frozen islets, suggesting significant oxidative 
stress during cryopreservation. As proof-of-concept, we utilised mitochondrial-targeted antioxidant MitoQ to 
reduce mitochondrial injury and demonstrated improved post-thaw viability and mitochondrial health. While 
these experiments support a role for oxidative damage during cryopreservation, further studies will be required 
to systematically test the efficacy of MitoQ to enhance cryopreservation of pancreatic islets.
Our findings suggest that current clinical viability staining protocols fail to assess the viability of the islet 
core. Because central necrosis of cultured islets is  common41, viability of islet batches is often overestimated and 
does not correlate with  function42. In this study, we identified two limitations of current viability assessment: 
insufficient staining times and inability to image the core of islets due to challenging optical properties of  islets43. 
Although light sheet fluorescence microscopy was the most successful technique in imaging the islet core, its use 
in clinical assessment is hampered by practical and logistic challenges. Strategies to overcome these challenges 
include flattening islets using the method described in Supplementary Fig. 1 (for high-throughput screening) or 
the use of dyes emitting at longer wavelengths (red/near infrared dyes) for greater depth of  imaging44.
The use of trehalose in combination with DMSO for cryopreservation was previously reported by studies in 
adult and fetal-like pancreatic  islets25 and hydrogel-encapsulated  islets26, both adding trehalose simultaneously 
with DMSO. Here, we maximised the protective effect of trehalose by optimising incubation times. Although we 
were not able to quantify the diffusion rates of trehalose itself (lack of suitable labelling and imaging modalities), 
the beneficial effects of trehalose were observed with 6 h pre-incubation, which correlated with the outcomes 
of the diffusion studies using Hoechst 33342. Prolonged pre-incubation with trehalose has been reported to 
improve DMSO-based cryopreservation in single cell models, to allow time for passive diffusion to the intracel-
lular  space45,46, but this is the first reported study to use it for enhanced diffusion into multicellular aggregates. 
The size of islets is expected to have an impact of the efficacy of the cryopreservation protocol. Data from the 
diffusion kinetics experiments suggest that the optimal pre-incubation time will be greater with increasing 
diameter. A given incubation time will thus only be optimal for a subset of islets in a heterogeneous batch. While 
sorting islets based on size is unlikely to be a feasible approach, determining the average islet size and adjust-
ing the incubation time accordingly could help account for inter-donor variability in size distribution. Precise 
estimation of the relationship between islet size and incubation time should be investigated in future studies.
Addition of trehalose in the DT6h protocol improved post-thaw viability. Several hypotheses have been pro-
posed to explain the cryoprotective effect of trehalose: stabilising proteins and membranes by water  replacement47 
or by their preferential  hydration48,49, ability to vitrify and thus prevent crystal  formation50 or antioxidative 
 properties51,52. In our case, it is expected that trehalose remains primarily in the extracellular space, although 
some trehalose may cross the membrane by passive  diffusion53 or during lipid-phase  transition25. Even extracel-
lular trehalose has been shown to deliver cryoprotective effect but further improvements of our protocol could be 
potentially be made through intracellular trehalose  delivery54–56. Interestingly, 24 h after thawing, islets consist-
ently displayed bi-modal viability distribution. The viability correlated with the islet size, suggesting that there 
may be an advantage for larger islets. We postulate a hypothesis where the survival of each islet is dependent on 
a critical amount of live cell–cell contact. If such trophic signals are below a critical threshold, the islet rapidly 
disintegrates. However, the validity of this hypothesis needs to be investigated in further studies.
While the presence of dead cells in cryopreserved samples makes some comparisons between conditions 
complicated, ATP/ADP, mtDNA oxidation and cAMP assays were crucial to confirm that the energetic and 
intracellular signalling pathways are still intact in cryopreserved islets. Release of peptides from α-cells (glucagon) 
and δ-cells (SST-14) appeared dysregulated in both fresh and frozen islets, possibly due to collagenase digestion 
damage of the islet periphery where α- and δ-cells are  located57. Peptides from β-cells (insulin-1 and 2, IAPP) 
were released by fresh islets as expected in response to elevated glucose concentrations, with DT6h-cryopreserved 
islets following similar fold changes. DMSO-cryopreserved islets, on the other hand, showed a decrease in fold 
changes for these peptides, which may be due to dysregulation or passive release of stored insulin from damaged 
islets. Of note, the decrease in oxidative phosphorylation detected by the transcriptomic analysis in both DMSO 
and DT6h islets could explain some of the changes in glucose-stimulated peptide release.
Both cryopreserved groups exhibited gene expression profiles expected in cells undergoing stress: upreg-
ulation of cell death and apoptotic genes, shift away from oxidative phosphorylation and increase in pro-
inflammatory markers. There is increasing evidence that metabolic stress in diabetes leads to the loss of β-cell 
 differentiation58. Together with changes in cell–cell interactions, this could explain the reason for upregulation 
of the ‘epithelial-mesenchymal transition’ gene set in both DMSO and DT6h groups. Overall, the transcriptome 
profiles of DMSO and DT6h were very similar and therefore, the effect of DT6h is unlikely to be mediated 
through large-scale changes in transcriptional programmes. Detected differences included lower expression 
of inflammatory, proliferative and apoptotic genes in the DT6h group. DMSO also showed significant down-
regulation of the ‘cholesterol homeostasis’ gene set compared to fresh group, while DT6h had closer profile to 
fresh islets for these genes. This is in line with higher gene expression of cholesterol precursor (Fdps), enzymes 
involved in cholesterol biosynthesis (Lss, Msmo1) and regulators of cholesterol concentration (Pcsk9, Insig1) in 
DT6h compared to DMSO group. Interestingly, cholesterol is known to have a membrane stabilising effect and 
has been shown to improve membrane integrity after cryopreservation of  sperm59. Cryopreservation inevitably 
results in membrane damage and replenishment of fatty acids and cholesterol may indicate ongoing membrane-
rebuilding processes. It appears that DMSO-cryopreserved islets show significant disruption in these processes 
and addition of trehalose partially prevents the downregulation in the genes involved, although this must be 
further investigated.
In vivo evaluation of DMSO- and DT6h-cryopreserved islets revealed suboptimal performance of both 
groups. The likely reason is that the functional islet mass transplanted was not sufficient to consistently reverse 
hyperglycaemia. This is consistent with preliminary experiments where 300–400 fresh islets per animal were 
not sufficient to reliably reverse diabetes in all experimental animals. Cryopreservation decreased the viable islet 
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mass by up to 50%, reducing the likelihood of achieving normoglycaemia using 800 frozen islets. Further stud-
ies using higher doses of frozen islets or their combination with fresh islets are needed to further compare the 
in vivo efficacy of these two cryopreservation methods. Nevertheless, the observed reduction in glucose levels 
upon transplantation in most animals and achievement of normoglycaemia in some confirms that frozen islets 
are capable of producing insulin in vivo.
The result of the pilot human islet cryopreservation experiment showed that the DT6h cryopreservation 
protocol, developed using mouse islets, had similar efficacy compared to DMSO alone for cryopreservation of 
human islets. Adaptation of mouse cryopreservation protocol to human islets will thus require further optimisa-
tion. Human islets differ significantly from mouse islets in many aspects. The majority of human islets are  small14, 
with the proportion of β-cells lower in smaller islets. Moreover, β-cells populate the central part of mouse islets, 
whereas they are more evenly distributed both in the centre and in the periphery in human  islets60. Shorter 
incubation times may thus be necessary for trehalose and DMSO to reduce cryoprotectant toxicity to β-cells. 
Other variations in the protocol that should be explored include the concentrations of DMSO and trehalose or 
temperature of the pre-incubation.
To conclude, by investigating diffusion properties of molecules in aqueous solutions into the core of multi-
cellular aggregates, we established the basis for design of cryopreservation protocols utilising non-penetrating 
cryoprotectants or incubations with therapeutic agents aimed to pre-condition islets before transplantation. The 
methods to study diffusion and the diffusion rates identified here can be utilised in other multicellular aggregate 
models, such as healthy and cancer organoids and bioengineered tissues. The optimised cryopreservation method 
for islets, developed here using this approach, provided improvement particularly in viability, mitochondrial 
health and peptide release from β-cells. By combining these better quality cryopreserved pancreatic islets with 
fresh islets, we could reduce the direct need for this limited resource and make transplantation accessible for 
more patients.
Methods
Animals. All procedures were performed under project licences (PPL numbers 70/8702 and 80/2638) 
approved by the United Kingdom Home Office under the Animal (Scientific Procedures) Act 1986 in accord-
ance with relevant guidelines and regulations (including ARRIVE guidelines). Male C57BL/6JAX mice were 
purchased from Charles River, UK and subsequently used for isolation of mouse pancreatic islets at the age of 
5–12  weeks. Fully immunodeficient NSG (NOD.Cg-PrkdcscidIL2rgtm1Wjl/SzJ, NOD scid gamma) mice, which 
lack B, T and NK  lymphocytes61 were bred in-house, litters weaned at three weeks of age and used for experi-
ments between 6 and 13 weeks of age. All animals were housed and maintained in University Biomedical Ser-
vices, University of Cambridge facility under specific-pathogen-free conditions. Mice were maintained follow-
ing standard husbandry procedures in the animal facility, with ad libitum access to water and dried food pellets 
unless otherwise specified during experimental procedure.
Islet isolation and culture. C57BL/6JAX mice were sacrificed by neck dislocation. Laparotomy was per-
formed and two clamps were placed on the bowel, one on each side of the ampulla to prevent leaking of the 
perfusate into the bowel. 2.5 mL solution of collagenase XI (Sigma Life Science, 1000 U/mL in HBSS medium, 
Gibco) was slowly injected into the pancreas via the bile duct (which joins the pancreatic duct), starting from the 
gall bladder using a 30 G bevelled needle. The pancreas was then carefully excised, placed into a 50 mL Falcon 
tube containing another 2 mL of collagenase XI solution and kept on ice until pancreases from all animals were 
retrieved. Tubes were incubated at 37 °C in a water bath and shaken every 5 min until the tissue was digested 
into a fine suspension (typically 12–18 min). Digestion was then terminated by adding 25 mL of ice-cold solu-
tion of HBSS supplemented with 1 mM  CaCl2 into each tube and centrifuging at 300g for 1 min at 4 °C. Two 
more washes with HBSS +  CaCl2 were performed and the digest in each tube was then resuspended in 10 mL 
Histopaque 1077 Hybri Max™ (Sigma Aldrich) at room temperature. 5 mL room temperature RPMI medium 
(Gibco) was carefully layered on top of the Histopaque and tubes were centrifuged at 800g for 15 min at 20 °C 
without brake. The islet-enriched layer was collected on the interface of Histopaque and RPMI into a fresh tube, 
topped up with RPMI and centrifuged at 300g for 3 min. The pellet was transferred into a 100 mm Petri dish. Full 
purification was achieved by manual handpicking of islets under inverted microscope. A single pancreas yielded 
approximately 150 islets. These were subsequently cultured in RPMI (Gibco) + 10% fetal calf serum (FCS, Sigma 
Life Sciences) + 1% Penicillin/Streptomycin (Gibco) at 37 °C and 5%  CO2 in humidified atmosphere for 1–7 days 
before being used for further experiments. Islets were checked for viability (> 95%) prior to the start of any 
experiment. Exact mouse islet counts in each experiment were determined by manual counting.
Diffusion studies. Fresh mouse pancreatic islets were pre-stained with 400 μg/mL Hoechst 33342 nucleic 
acid stain (ThermoFisher) under different conditions (variations in temperature, DMSO concentration and g 
force). At the end of the incubation time, islets were washed in a Petri dish with 5 mL PBS and handpicked 
with minimal volume of medium (~ 10 μL) into a Peel-A-Way embedding conical mould (Polysciences, Inc.). 
60–80 μL of Optimal Cutting Temperature Compound (OCT) was carefully mixed with the handpicked islets at 
the bottom of the mould to avoid bubbles and the drop was frozen on dry ice. Once rigid, the block was covered 
with more OCT, frozen on dry ice and stored at − 80 °C until sectioning. Cryo-sectioning of temperature-equil-
ibrated OCT blocks was performed using Hacker Bright OTF5000 cryostat (Hacker Instruments and Industries 
Inc.) at a thickness of 11 μm. Sections were transferred to a room temperature microscope slide and frozen 
immediately on dry ice to avoid dehydration and further diffusion of molecules. Slides were kept on dry ice and 
were only removed during imaging. Prior to imaging, coverslips were mounted onto the slides using a dry mount 
method with double-sided tape. Wet mounting was not suitable since it allowed movement of dye molecules 
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across the samples. Imaging was performed using the Leica Sp5 (Leica Microsystems) inverted confocal micro-
scope as described below. Bright field and fluorescent images of 3–10 islet sections were taken for each experi-
mental condition. Only round islets were included in the analysis as the image analysis method was not suitable 
to analyse irregularly shaped or elliptical islets. Image analysis was done in ImageJ plugin Concentric Circles 
(Inner Radius = 5.0, Outer Radius = fitted to outer edge of islet, number of Circles: calculated to be 5 px apart).
Imaging. Wide-field images were collected using the Olympus IX81 inverted fluorescence microscope 
(Olympus) equipped with FITC, TRITC and DAPI filter set. Laser scanning confocal microscopy was performed 
using an inverted Leica Sp5 (Leica Microsystems). Detection band widths were set for each fluorochrome 
according to its spectral properties. Collection of images and simple pre-processing steps were performed using 
the LAS X software (Leica Microsystems). Multiphoton images were taken using the TriM Scope II (LaVision 
BioTec) upright 2-photon scanning fluorescence microscope, using appropriate set of wide bandpass emission 
filters. For light-sheet microscopy, pancreatic islets stained with combination of fluorescent dyes were embedded 
in 1% low melting agarose and drawn into a glass capillary. Once the agarose solidified, the capillary was inserted 
into the holder of the microscope and imaged using the Zeiss Lightsheet Z.1 (Zeiss). The excitation/emission 
wavelengths were 405/415 for Hoechst 33342, 488/498 for FDA and 561/571 for PI.
Islet cryopreservation. Islets were handpicked into 1.8 mL cryovials and cryoprotectant was added accord-
ing to the experimental protocol. All cryoprotectant solutions were prepared in RPMI (Gibco) + 10% FCS. Stand-
ard cryopreservation protocol (DMSO) consisted of three additions of DMSO over 45 min to gradually increase 
its concentration (5 min in 0.66 M DMSO at room temperature, 25 min in 1 M DMSO at room temperature and 
15 min in 2 M DMSO at 4 °C). In DT6h and DT6h + MitoQ conditions, islets were pre-incubated for a specified 
time with 200 mM trehalose (D-( +)-trehalose dihydrate, Sigma Life Sciences) or 200 mM trehalose + 100 nM 
MitoQ, respectively, before the stepwise addition of DMSO described above. Freezing was performed using the 
CRF-1 controlled rate freezer (Grant) set to a following programme: freezing from 4 to − 7.4 °C at the rate of 
− 2 °C/min, holding at − 7.4 °C for 15 min, freezing to − 40 °C at the rate of − 0.3 °C/min. Vials were then plunged 
into liquid nitrogen and stored in the liquid phase until thawing. To thaw, samples were removed from liquid 
nitrogen and rapid thawing in a 37 °C water bath was performed until the last ice crystal was visible. Dilution of 
the cryoprotectant with culture medium (RPMI + 10% FCS) was performed using the slow step dilution protocol 
described  previously31, achieving 10× dilution of the cryoprotectant. Islets were handpicked into a Petri dish 
containing culture medium and either used immediately or cultured for 24 h. Preparation of islets from a group 
of animals on the same occasion was considered as one isolation and treated as a biological replicate.
Viability, size and yield assessment. Fresh or frozen/thawed islets were handpicked and placed in 
200 μL of PBS. Islets were stained with 5 μg/mL propidium iodide (PI, Sigma-Aldrich) and 5 μg/mL fluores-
cein diacetate (FDA, Sigma-Aldrich) for 15 min protected from light. Stained samples were diluted with 2 mL 
PBS, handpicked onto a glass cover slip, covered by a second cover slip and imaged immediately by Olympus 
IX81 microscope with constant imaging parameters for all samples. Quantitative analysis of the images was 
performed using ImageJ. Manual threshold (same for all images) was applied to select the positive area in the 
appropriate colour channel and viability was determined as a ratio of FDA positive area and total (FDA + PI) 
positive area. To calculate post-thaw islet yield, number of islets recovered post-thaw was divided by number of 
islets prior to freezing. For size measurements, pre-freeze or thawed islets (immediately or 24 h post-thaw) were 
transferred into a Petri dish and bright field images of all islets were taken at 4× magnification. Diameter of each 
islet was manually measured using ImageJ.
ATP/ADP ratio assay. 50 pancreatic islets per condition were handpicked into a 1.5 mL Eppendorf tube and 
adenonucleotides were extracted by adding 1 mL of ice-cold perchloric acid (3% v/v  HClO4, 2 mM  Na2EDTA, 
0.5% Triton X-100) followed by vortexing. Extracted samples were stored at − 80 °C until ATP and ADP quantifi-
cation using luciferase-based assay described by  Strehler62. Briefly, ATP and ADP standard curves were prepared 
by serial dilutions in perchloric acid from 20 mM stock solutions of ATP and ADP sodium salts (Sigma). 400 μL 
of each sample was pH-neutralised using ice-cold KOH solution (2 M KOH, 2 mM  Na2EDTA, 50 mM MOPS) 
until white  KClO4 precipitate formed. Samples were centrifuged (17,000g, 1 min, 4 °C) and supernatant used for 
further measurements. 250 μL of sample supernatant was prepared for quantification of ADP by degradation of 
endogenous ATP by incubating the supernatant with 250 μL ATP sulfurylase assay buffer (20 mM  Na2MoO4, 
5 mM GMP, 0.2 U ATP sulfurylase (New England Biolabs), in Tris–HCl buffer (100 mM Tris–HCl, 10 mM 
 MgCl2 (pH 8.0))) for 30 min at 30 °C while shaking, followed by heating to 100 °C for 5 min and cooling on 
ice. 100 μL of standards, one 100 μL sample for ATP measurement and two 200 μL samples for ADP measure-
ment were mixed in luminometer tubes with 400 μL Tris–acetate buffer (100 mM Tris, 2 mM  Na2EDTA, 50 mM 
 MgCl2, pH adjusted to 7.75 with glacial acetic acid). To one of the ADP measurement samples, 10 μL pyruvate 
kinase solution (100 mM PEP, 6 U pyruvate kinase suspension (Sigma)) was added and incubated for 30 min 
at 25 °C in the dark to convert ADP to ATP. The other ADP measurement sample remained unconverted and 
served as a blank. 100 μL Luciferase/Luciferin Solution (7.5 mM DTT, 0.4 mg/mL BSA, 1.92 μg luciferase/mL 
(Sigma), 120 μM d-luciferin (Sigma), in Tris-acetate buffer (25% v/v glycerol)) was auto-injected and luciferase 
luminescence measured using the Berthold AutoLumat Plus luminometer three times for 1 min and the data 
quantified against standard curves using MS Excel.
mtDNA oxidation assay. Oxidation of mtDNA was assayed by quantitative polymerase chain reaction 
(PCR) using two targets: a short target (≥ 200 bp), to control for the mtDNA copy number, and a long target 
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(~ 10 kbp), for which reduced amplification corresponds to oxidative DNA  damage35,36. DNA was isolated from 
50 fresh or thawed pancreatic islets using GenElute™ Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich) 
according to manufacturer’s instructions and DNA stored at − 20 °C until the assay. Prior to the assay, DNA con-
centration in the thawed samples was measured using NanoDropTM 8000 Spectrophotometer (ThermoFisher 
Scientific) and samples were diluted to 3 ng/mL. The PCR mastermix contained 200 μM dNTPs (TμaKaRa), 
200 pM forward primer (Sigma, 5′-GCC AGC CTG ACC CAT AGC CAT AAT-3′), 200 pM reverse primer 
(Sigma, 5′-GCC GGC TGC GTA TTC TAC GTT A-3′ for short target, 5′-GAG AGA TTT TAT GGG TGT AAT 
GCG G-3′ for long target), 100 ng/mL BSA (New England Biolabs) and 1 mM Mg (OAc)2 (TaKaRa) in buffer 
(TaKaRa). Reaction was performed in PCR tubes and each reaction consisted of 5 μL (15 ng) of DNA template 
from samples, 35 μL of PCR mastermix and 1 U of LA Taq polymerase (TaKaRa). Reactions were performed 
in duplicates, including non-template control and linear amplification control. Reactions were then performed 
using 22 cycles for short target and 25 cycles for long target. PCR products were quantified using the Quant-iT™ 
PicoGreen™ dsDNA Assay Kit (ThermoFisher Scientific) according to manufacturer’s instructions and the size of 
the PCR product was checked on a 0.8% agarose gel. For the analysis in Excel, all samples were corrected to the 
non-template control and normalised to amplification of the short target.
cAMP assay. Fresh or thawed pancreatic islets (150–200 islets/condition) were dissociated into single cells 
using 5  min incubation with 0.05% trypsin + 0.53  mM EDTA (Sigma-Aldrich) and mechanical disruption 
with p1000 pipette. Dissociation was stopped by addition of RPMI + 10% FCS and cells were counted using 
haemocytometer. Measurements of cAMP were performed using  LANCE® cAMP Detection Kit (PerkinElmer) 
in accordance with the manufacturer’s instructions. Assay was run in duplicates or triplicates, using 4000 cells 
per well in 384-well OptiPlate (PerkinElmer). Forskolin (Sigma Aldrich), GLP-1(7–26)amide (Alta Biosciences), 
cAMP standard or DMSO control were diluted in stimulation buffer (PBS supplemented with 0.1% BSA (Sigma-
Aldrich, A2153) and 0.5  mM of the non-specific inhibitor of cAMP and cGMP phosphodiesterases (PDEs) 
3-Isobutyl-1-methylxanthine (IBMX) (Sigma-Aldrich)) to the appropriate concentration (final concentration of 
 10–4 M forskolin,  10–5 or  10–6 M GLP-1(7–36)amide in assay). Measurements were taken using a Mithras LB 940 
microplate reader (Berthold Technology); excitation 340 nm and emission 665 nm.
Peptidomics. Fresh or thawed pancreatic islets were thoroughly washed from any leftover cryoprotectant 
(to avoid an effect of remaining trehalose on the insulin secretion). Islets were acclimatised for 30 min in pre-
warmed 3.3 mM glucose Krebs–Ringer Bicarbonate Buffer (KRB (mM): 137 NaCl, 4.7 KCl, 1.2  KH2PO4, 1.2 
 MgSO4·7H2O, 2.5  CaCl2·2H2O, 25  NaHCO3). Islets were washed once in fresh 3.3 mM KRB before assay. Each 
condition was tested in triplicates. 10 islets were handpicked into 1.5 mL Protein LoBind tubes (Eppendorf) and 
incubated with 500 μL of 3.3 mM KRB for 1 h in a humidified chamber at 37 °C. Then, tubes were mixed and 
spun in a microcentrifuge (300g for 30 s) and all supernatant transferred into a new Protein LoBind tube and 
stored at − 80 °C. Next, same islets were incubated with 500 μL of 16.7 mM glucose KRB for 1 h at 37 °C while 
shaking, then mixed, centrifuged and the supernatant taken out into a new Protein LoBind tube. Supernatants 
were stored at − 80 °C until analysis by liquid chromatography tandem mass spectrometry (LC–MS/MS). Prior 
to protein extraction, islet supernatants were thawed on ice and acidified with 50 μL 1% formic acid in  H2O (v/v). 
A stable isotope-labelled internal standard (IS) for glucagon was spiked into the samples for a final concentration 
of 20 ng/mL. Samples were loaded onto a HLB Prime μElution plate (Waters) for solid phase extraction (SPE). 
200 μL 0.1% formic acid in  H2O was used to wash the wells prior to a wash with 200 μL 1% acetic acid and 5% 
methanol in  H2O (v/v/v). Peptides were eluted into a Protein LoBind 96 well plate (Eppendorf) with 2 separate 
elutions of 30 μL 10% acetic acid, 10% methanol. 40 μL 0.1% formic acid in  H2O was added to all samples to prior 
to LC–MS/MS analysis to reduce the organic solvent composition of the extract. A H-Class Aquity (Waters) 
LC system coupled to a Xevo TQ-XS triple quadrupole mass spectrometer (Waters) was used to quantify islet 
derived peptide hormones in supernatants. 40 μL of sample was loaded onto a 2.1 × 50 mm 1.8 μm particle HSS 
T3 Aquity column at 60 °C flowing at 350 μL/min with gradient starting conditions set to 90% solvent A (0.1% 
formic acid in  H2O) and 10% solvent B (0.1% formic acid in acetonitrile (Pierce) (v/v)) for 30 s. The percentage 
of solvent B was gradually increased to 50% over 7.5 min, and the column was washed with 90% solvent B for 
2 min before returning to initial conditions with a total run time of 10 min. LC–MS/MS analysis was performed 
using positive electrospray ionisation (ESI) with a spray voltage of 3 kV, desolvation temperature 600 °C, gas 
flow rate 1000 L/h and cone voltage of 40 V. Table 1 details the precursor and product ions for each of the islet 
Table 1.  Parameters of LC–MS/MS analysis. Precursor and precursor ions along with collision energies and 
dwell time used to monitor each peptide during LC–MS/MS analysis.
Peptide Precursor (m/z) Product (m/z) Collision energy Dwell time (ms)
Insulin-1 967.8 331.2 40 0.025
Insulin-2 1159.7 334.1 40 0.025
IAPP 980.5 958.2 20 0.025
Glucagon 871.5 1040.2 27 0.025
Glucagon IS 877.1 1047.2 27 0.025
Somatostatin-14 546.6 726.3 15 0.025
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hormones analysed in addition to collision energies and dwell times. Peptides were quantified by integrating the 
corresponding peaks using TargetLynx v4.2 software (Waters). Raw peak area values are reported as a measure of 
peptide abundance in the sample apart from glucagon which is normalised to its internal standard and presented 
as peak area ratio.
RNA sequencing. Isolated pancreatic islets were cultured for 24 h and split into three groups: fresh, DMSO 
and DT6h. In the fresh group, 200 islets were centrifuged (300g, 1 min) and the pellet resuspended in 100 μL 
RNAlater solution (LifeTechnologies) and then stored at − 20 °C until RNA isolation. In the DMSO and DT6h 
groups, 200 islets were cryopreserved using either the standard DMSO or DT6h cryopreservation protocol 
described above. After thawing, islets were cultured for 24 h, after which the islets from each group were cen-
trifuged (300g, 1 min), resuspended in 100 μL RNAlater solution (LifeTechnologies) and stored at -20 °C until 
RNA isolation. Total cellular RNA was isolated using a Qiagen RNeasy Plus Micro kit (Qiagen). Briefly, 0.5 mL 
cold PBS was added to each pancreatic islet sample, gently mixed by inversion and the islets spun down at 600g 
for 5 min in a microfuge. The pellet was resuspended and lysed in 350 μL RLT Plus buffer. The resulting lysate 
was then passed over a QIA Shredder column (Qiagen) to optimise homogenisation of the resulting lysate. 
Subsequent steps in RNA isolation were according to the manufacturer’s instructions. Total RNA was eluted in 
a volume of 14 μL RNAse-free water, snap-frozen on dry ice and stored at − 80 °C. RNA quality and quantity 
were measured on an Agilent 4200 TapeStation system and 50  ng used for subsequent library construction. 
Ribosomal RNA was removed using the QIA FastSelect RNA Removal kit (Qiagen), with a 10 min incubation at 
95 °C, to produce insert sizes in the 150–250 bp range. Strand-specific libraries were then constructed using the 
QIAseq Stranded Total RNA Library kit (Qiagen) according to the manufacturer’s instructions. Library quality 
was assessed on an Agilent 4200 TapeStation system and quantified by qPCR using the QIAseq Library Quant 
Assay kit (Qiagen). Libraries were pooled to an equimolar ratio and single-end (50 bp reads) sequencing carried 
out on a HiSeq 4000 to an average depth of 26.7 million reads per library. FastQ files were demultiplexed using 
bcl2fastq (Illumina), trimmed using TrimGalore! and mapped to the mouse genome (GRCm38) using HiSat2. 
Bam files were read into  SeqMonk39 (Babraham Institute, Cambridge) for read quantitation and library normali-
sation. Differentially expressed genes were identified separately by  DESeq238 and the Intensity Difference  filter40 
(a fold-change filter weighted for gene expression). A set of genes common to both the DESeq2 and Intensity 
Difference filters was used for some visualisations. For pathway analysis, Gene Set Enrichment Analysis (GSEA) 
was run in pre-ranked mode (GSEA-Preranked) against the Hallmark gene set collection from the Molecular 
Signatures Database (MSigDB) and C5 Gene Ontology: Biological Process gene  sets63. The inverse of the raw 
p-value was used as a ranking metric. The direction of change in expression was given by the sign of the log fold 
change. Gene sets with an FDR q-value ≤ 0.05 were considered significant. Plots were produced using GraphPad 
Prism (version 8.4.1) or SeqMonk (version 1.45.4).
Transplantation of islets into STZ‑diabetic mice. Streptozotocin (STZ, Sigma Life Science) solution 
was prepared on the day of the injection by dissolving STZ powder in freshly prepared citrate buffer (0.1 M citric 
acid + 0.1 M sodium citrate, pH 4.2) at 10 mg/mL and kept on ice until the injections. NSG mice were weighed, 
anaesthesised using mixture of isoflurane and oxygen and injected with 40 mg/kg STZ intraperitoneally on 5 
consecutive days using 30 G needle. In addition to their regular chow, mice were fed mash made of powdered 
diet with the same composition to prevent weight loss for the duration of the experiment. Mice were weighed 
and blood glucose was measured using iHealth Smart Gluco-Monitoring system (iHealth Labs) by tail vein 
bleeds before the first injection of STZ and then weekly until the end of the experiment after 6 h of fasting. 
Mice were considered diabetic when their fasting blood glucose reached over 13.5 mmol/L and used for trans-
plantation when fasting blood glucose reached over 18 mmol/L. Diabetic animals were transplanted with 800 
fresh or DMSO- or DT6h- cryopreserved islets resuspended in Matrigel (Corning) under the kidney capsule. 
Preliminary optimisation of transplanted islet dose (testing 300, 400 and 800 islets per animal) was performed 
in a similar manner. Animals were culled at > 20% weight loss (1 animal in the Matrigel group) or 75 days after 
transplantation. At the endpoint, blood was collected for serum using inferior vena cava bleed under terminal 
anaesthesia. To extract serum, samples were kept at 4 °C for 24 h after collection to allow for coagulation and 
spun in a microcentrifuge at 13,000g for 7 min. Clear serum was collected from the top supernatant layer and 
samples were stored at − 20 °C until analysis. Serum glucose was measured using a colorimetric assay on the 
Siemens Dimension EXL autoanalyser. All reagents and calibrators were supplied by Siemens.
Cryopreservation of human pancreatic islets. Pancreatic islets were isolated from pancreases of 
human deceased organs donors by SNBTS Islet Cell Laboratory in Edinburgh (ethical approval REC Ref: 16/
WM/0093). These clinically isolated islets were declined for transplantation due to low purity, viability or yield 
and subsequently offered for research use. They were shipped in CMRL 1066 Supplemented culture media 
(Corning) at room temperature and further processed upon arrival. The purity and viability of the received 
islets was validated upon receipt in our laboratory using dithizone staining and fluorescein diacetate/propidium 
iodide staining. Clinical and islet isolation information about human islet preparations can be found in Supple-
mentary Table 1. Islets were cryopreserved and viability was tested using the same protocol as for mouse islets, 
CMRL 1066 was used instead of RPMI, islet counts were determined by manual handpicking.
Statistical analysis. Sample sizes for in vitro and in vivo experiments were computed using the G*Power 
software (version 3.1) prior to the experimental work. Effect size was based on data available from a pilot experi-
ment, power was set to 80% and α error probability to 0.05. Statistical analysis was performed using the Graph-
Pad Prism software (version 8.4.1) using t-test, one-way or two-way ANOVA followed by Tukey’s, Sidak’s or 
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Dunnett’s post-hoc tests as appropriate. Differences were considered statistically significant if p-value ≤ 0.05. In 
graphs, individual data points or mean values ± SD are shown. Correlations were evaluated using Spearman’s 
correlation coefficient and reported along with p-values. Results obtained from viability staining of pancreatic 
islets at 24 h after thawing followed bimodal distribution. Calculation of means using standard methods was 
used as an approximation to determine average viability of each sample. These means then followed Gaussian 
distribution and were analysed using standard methods described above. Animals were randomly assigned to 
treatment groups; littermates were used, and data was analysed blinded to the group identity.
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